How It Works : Aqualyx is injected directly into the targeted fat area using a fine needle
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach
This multi-receptor approach is intended to enhance metabolic regulation by combining appetite suppression, energy expenditure, and glucose control within a single compound
The purpose of this research was to identify their needs along their journey with a GLP-1
This action makes these agents a therapeutic option for weight loss.56 Although to a lesser extent, delay in gastric emptying contributes to the anorexigenic effect.61 Clinical trials conducted with GLP-1 receptor agonists in patients with obesity (or excess weight [BMI 27] with comorbidities), or with DT2 and excess weight or obesity, have achieved weight reductions greater than those reported for orlistat, as well as those observed with oral antidiabetic agents such as the sodium glucose type 2 cotransporter inhibitors (SGLT2i) or metformin.62 In a meta-analysis of more than 10 000 patients with obesity, those treated with GLP-1 receptor agonists lost, on average, 7kg more than those in the control group.63 Weight loss of up to 15% has been observed after 12 months of treatment,64,65 a level that had only been achieved through surgical methods
Unlock rapid recovery with the Wolverine Stack
